TVTX Travere Therapeutics Inc
Price (delayed)
$17.94
Market cap
$1.59B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.08
Enterprise value
$1.94B
Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this
Highlights
Travere Therapeutics's gross profit has surged by 68% YoY and by 16% QoQ
The revenue has surged by 61% year-on-year and by 15% since the previous quarter
TVTX's net income has dropped by 189% year-on-year but it is up by 9% since the previous quarter
The company's EPS has shrunk by 172% YoY but it rose by 11% QoQ
TVTX's equity has dropped by 71% year-on-year
Key stats
What are the main financial stats of TVTX
Market
Valuations
Earnings
Shares outstanding
88.74M
Market cap
$1.59B
Enterprise value
$1.94B
Price to earnings (P/E)
N/A
Price to book (P/B)
23.7
Price to sales (P/S)
6.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.3
Revenue
$233.18M
Gross profit
$225.43M
Operating income
-$323.83M
Net income
-$321.55M
EBIT
-$310.24M
EBITDA
-$266.69M
Free cash flow
-$273.69M
Per share
Balance sheet
Liquidity
EPS
-$4.08
EPS diluted
-$4.08
Free cash flow per share
-$3.47
Book value per share
$0.76
Revenue per share
$2.96
TBVPS
$6.21
Total assets
$594.13M
Total liabilities
$535.05M
Debt
$401.58M
Equity
$59.08M
Working capital
$215.95M
Debt to equity
6.8
Current ratio
2.08
Quick ratio
1.98
Net debt/EBITDA
-1.29
Margins
Efficiency
Dividend
EBITDA margin
-114.4%
Gross margin
96.7%
Net margin
-137.9%
Operating margin
-138.9%
Return on assets
-55.6%
Return on equity
-1,091.5%
Return on invested capital
-46.8%
Return on capital employed
-78.9%
Return on sales
-133.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TVTX stock price
How has the Travere Therapeutics stock price performed over time
Intraday
2.87%
1 week
-13.71%
1 month
-16.17%
1 year
154.83%
YTD
2.99%
QTD
0.11%
Financial performance
How have Travere Therapeutics's revenue and profit performed over time
Revenue
$233.18M
Gross profit
$225.43M
Operating income
-$323.83M
Net income
-$321.55M
Gross margin
96.7%
Net margin
-137.9%
TVTX's net income has dropped by 189% year-on-year but it is up by 9% since the previous quarter
The net margin has dropped by 80% year-on-year but it is up by 20% since the previous quarter
Travere Therapeutics's gross profit has surged by 68% YoY and by 16% QoQ
The revenue has surged by 61% year-on-year and by 15% since the previous quarter
Growth
What is Travere Therapeutics's growth rate over time
Valuation
What is Travere Therapeutics stock price valuation
P/E
N/A
P/B
23.7
P/S
6.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.3
The company's EPS has shrunk by 172% YoY but it rose by 11% QoQ
The price to book (P/B) is 117% higher than the 5-year quarterly average of 10.6
TVTX's equity has dropped by 71% year-on-year
The revenue has surged by 61% year-on-year and by 15% since the previous quarter
The stock's P/S is 26% above its last 4 quarters average of 4.7 but 25% below its 5-year quarterly average of 7.9
Efficiency
How efficient is Travere Therapeutics business performance
Travere Therapeutics's return on equity has shrunk by 102% QoQ
The company's return on sales has shrunk by 94% YoY but it rose by 20% QoQ
Dividends
What is TVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TVTX.
Financial health
How did Travere Therapeutics financials performed over time
TVTX's total assets is 11% more than its total liabilities
The company's current ratio fell by 40% YoY but it rose by 22% QoQ
The quick ratio has decreased by 40% YoY but it has increased by 25% from the previous quarter
Travere Therapeutics's debt to equity has soared by 151% from the previous quarter
TVTX's equity has dropped by 71% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.